arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Tango Therapeutics, Inc.

TNGX Health Care Biotechnology: Pharmaceutical Preparations
$22.52
Today
as of Sep 4, 16:55 ET
Last 30 days -15.72% Jul 27 → Sep 04
$21.76 $23.80 $25.84 $27.88 $29.92 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$22.48
High
$22.94
Low
$22.29
Volume
$1M
Avg Vol
$3M
Mkt Cap
$4.3B
P/E (TTM)
—
Beta
—
52w High
$34.39
52w Low
$6.25
Div Yield
—
Shares Out
$168M

Recent Press Releases & News last 60 days · 13 items

Sep 4 · 07:08 Simply Wall St.
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey
Sep 3 · 21:26 MT Newswires
Tango Therapeutics Insider Sold Shares Worth $603,909, According to a Recent SEC Filing
Sep 3 · 20:05 PR GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 13 press releases & news Free account →

Overview

52-week range
$6.25
$34
58% of range
Avg surprise (last 3)
-2.0%
Avg reaction (last 2)
+11.7%
100% positive
Latest IV / EM
95%
EM ±14.9% · $23 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.37$-0.24$-0.12$0.01$0.13 Actual $-0.32Actual $-0.23Actual $-0.23Actual $-0.35Actual $-0.24Actual $-0.27Actual $-0.36Est $-0.34Actual $-0.35Est $-0.35Actual $0.13Actual $-0.32Est $-0.32Actual $-0.37 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-55M$-27M$580,275$29M$57M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.37 — — — — financials
Wed May 13, 2026Mar/2026 $-0.32 $-0.32 0.0% +11.1% +8.6% earnings
Tue Sep 30, 2025Sep 2025 $0.13 — — — — financials
Tue Aug 5, 2025Jun/2025 $-0.35 $-0.35 0.0% — — earnings
Mon May 12, 2025Mar/2025 $-0.36 $-0.34 -5.9% — +14.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.27 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.24 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.35 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.23 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.23 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.32 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$54M$3M$5M—$12M
Cost of revenue————————
Gross profit————————
Operating income$-60M$-49M—$14M$-41M$-43M—$-33M
Net income$-55M$-46M—$16M$-39M$-40M—$-29M
EPS (diluted)$-0.37$-0.32—$0.13$-0.35$-0.36—$-0.27

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$346M$158M$112M$58M$39M$58M$70M$53M
Inventory————————
Total current assets$1.03B$392M$354M$164M$190M$225M$266M$301M
Total assets$1.07B$436M$399M$210M$238M$274M$316M$352M
Long-term debt————————
Total liabilities$49M$44M$53M$50M$103M$108M$117M$123M
Total equity$1.02B$392M$346M$160M$135M$167M$200M$229M

Implied volatility — last 90 days

62%139%217%294%371% Jun 08 — IV 110% · EM ±14.6%Jun 09 — IV 106% · EM ±13.3%Jun 10 — IV 102% · EM ±12.0%Jun 11 — IV 102% · EM ±11.3%Jun 12 — IV 99% · EM ±10.1%Jun 15 — IV 128% · EM ±9.3%Jun 16 — IV 112% · EM ±6.6%Jun 17 — IV 294% · EM ±12.3%Jun 19 — IV 97% · EM ±21.4%Jun 22 — IV 87% · EM ±18.2%Jun 23 — IV 82% · EM ±16.7%Jun 24 — IV 81% · EM ±16.1%Jun 25 — IV 80% · EM ±15.7%Jun 26 — IV 74% · EM ±14.1%Jun 29 — IV 81% · EM ±14.3%Jun 30 — IV 71% · EM ±12.2%Jul 01 — IV 69% · EM ±11.5%Jul 02 — IV 65% · EM ±10.4%Jul 03 — IV 67% · EM ±10.4%Jul 06 — IV 71% · EM ±9.8%Jul 07 — IV 89% · EM ±11.8%Jul 08 — IV 89% · EM ±11.2%Jul 09 — IV 73% · EM ±8.6%Jul 10 — IV 77% · EM ±8.5%Jul 13 — IV 141% · EM ±11.7%Jul 14 — IV 79% · EM ±5.7%Jul 15 — IV 87% · EM ±5.1%Jul 16 — IV 147% · EM ±6.1%Jul 20 — IV 90% · EM ±21.2%Jul 21 — IV 81% · EM ±18.9%Jul 22 — IV 83% · EM ±19.0%Jul 23 — IV 75% · EM ±16.9%Jul 24 — IV 99% · EM ±22.0%Jul 27 — IV 96% · EM ±20.0%Jul 28 — IV 100% · EM ±20.5%Jul 29 — IV 79% · EM ±15.9%Jul 30 — IV 103% · EM ±20.3%Jul 31 — IV 82% · EM ±15.6%Aug 03 — IV 71% · EM ±12.5%Aug 04 — IV 99% · EM ±17.0%Aug 05 — IV 108% · EM ±18.1%Aug 06 — IV 85% · EM ±13.8%Aug 07 — IV 101% · EM ±15.8%Aug 10 — IV 98% · EM ±13.5%Aug 11 — IV 100% · EM ±13.3%Aug 12 — IV 101% · EM ±12.7%Aug 13 — IV 70% · EM ±8.3%Aug 14 — IV 109% · EM ±12.0%Aug 17 — IV 110% · EM ±9.2%Aug 18 — IV 75% · EM ±5.4%Aug 19 — IV 84% · EM ±5.0%Aug 20 — IV 372% · EM ±15.5%Aug 24 — IV 68% · EM ±14.2%Aug 25 — IV 71% · EM ±14.4%Aug 26 — IV 72% · EM ±14.5%Aug 27 — IV 63% · EM ±12.3%Aug 28 — IV 83% · EM ±16.0%Aug 31 — IV 65% · EM ±11.5%Sep 01 — IV 83% · EM ±14.3%Sep 02 — IV 86% · EM ±14.3%Sep 03 — IV 90% · EM ±14.5%Sep 04 — IV 95% · EM ±14.9%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in